Trial Condition(s):

Clinical Pharmacology

BAY59-7939, comparison of PK of Rivaroxaban and Apixaban

Bayer Identifier:

18359

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

2015-002612-32

Study Completed

Trial Purpose

To assess the plasma pharmacokinetics (PK) of
rivaroxaban and apixaban after multiple dosing and after
discontinuation of both.

Inclusion Criteria
:
  - Healthy male white subjects age 18 to 55 years (inclusive) with a
body mass index above or equal 18.0 kg/m² and below or equal
29.9 kg/m²
Exclusion Criteria
No Exclusion Criteria Available

Trial Summary

Enrollment Goal
N/A
Trial Dates
black-arrow
Phase
1
Could I receive a placebo?
No
Products
Xarelto (Rivaroxaban, BAY59-7939)
Accepts Healthy Volunteers
Yes

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Mönchengladbach, Germany, 41061

Status
Completed
 

For details, please refer to trial results

Additional Information